LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $100.20.

LMAT has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Wells Fargo & Company reduced their target price on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Roth Mkm restated a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th.

LeMaitre Vascular Trading Up 0.5%

LMAT opened at $87.42 on Friday. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 37.68, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. The company’s 50 day simple moving average is $84.53 and its two-hundred day simple moving average is $87.66. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $105.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The firm had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 earnings per share. Analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank & Trust increased its holdings in LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 287 shares during the last quarter. Cornerstone Planning Group LLC boosted its position in shares of LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares during the period. MAI Capital Management acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at $38,000. First Horizon Corp purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at $39,000. Finally, Geneos Wealth Management Inc. lifted its stake in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.